These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
480 related articles for article (PubMed ID: 20127862)
1. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance. Shao W; Growney JD; Feng Y; O'Connor G; Pu M; Zhu W; Yao YM; Kwon P; Fawell S; Atadja P Int J Cancer; 2010 Nov; 127(9):2199-208. PubMed ID: 20127862 [TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma. Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859 [TBL] [Abstract][Full Text] [Related]
3. Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism. Chen J; Fiskus W; Eaton K; Fernandez P; Wang Y; Rao R; Lee P; Joshi R; Yang Y; Kolhe R; Balusu R; Chappa P; Natarajan K; Jillella A; Atadja P; Bhalla KN Blood; 2009 Apr; 113(17):4038-48. PubMed ID: 19074726 [TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Ellis L; Pan Y; Smyth GK; George DJ; McCormack C; Williams-Truax R; Mita M; Beck J; Burris H; Ryan G; Atadja P; Butterfoss D; Dugan M; Culver K; Johnstone RW; Prince HM Clin Cancer Res; 2008 Jul; 14(14):4500-10. PubMed ID: 18628465 [TBL] [Abstract][Full Text] [Related]
5. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer. Garrett LA; Growdon WB; Rueda BR; Foster R J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667 [TBL] [Abstract][Full Text] [Related]
6. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo. Catalano MG; Pugliese M; Gargantini E; Grange C; Bussolati B; Asioli S; Bosco O; Poli R; Compagnone A; Bandino A; Mainini F; Fortunati N; Boccuzzi G Int J Cancer; 2012 Feb; 130(3):694-704. PubMed ID: 21400508 [TBL] [Abstract][Full Text] [Related]
7. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity. Woods DM; Woan K; Cheng F; Wang H; Perez-Villarroel P; Lee C; Lienlaf M; Atadja P; Seto E; Weber J; Sotomayor EM; Villagra A Melanoma Res; 2013 Oct; 23(5):341-8. PubMed ID: 23963286 [TBL] [Abstract][Full Text] [Related]
8. Combined inhibition of Bcl-2 and NFκB synergistically induces cell death in cutaneous T-cell lymphoma. Froehlich TC; Müller-Decker K; Braun JD; Albrecht T; Schroeder A; Gülow K; Goerdt S; Krammer PH; Nicolay JP Blood; 2019 Aug; 134(5):445-455. PubMed ID: 31167801 [TBL] [Abstract][Full Text] [Related]
9. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Fantin VR; Loboda A; Paweletz CP; Hendrickson RC; Pierce JW; Roth JA; Li L; Gooden F; Korenchuk S; Hou XS; Harrington EA; Randolph S; Reilly JF; Ware CM; Kadin ME; Frankel SR; Richon VM Cancer Res; 2008 May; 68(10):3785-94. PubMed ID: 18483262 [TBL] [Abstract][Full Text] [Related]
10. DAPK plays an important role in panobinostat-induced autophagy and commits cells to apoptosis under autophagy deficient conditions. Gandesiri M; Chakilam S; Ivanovska J; Benderska N; Ocker M; Di Fazio P; Feoktistova M; Gali-Muhtasib H; Rave-Fränk M; Prante O; Christiansen H; Leverkus M; Hartmann A; Schneider-Stock R Apoptosis; 2012 Dec; 17(12):1300-15. PubMed ID: 23011180 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat). Kubo M; Kanaya N; Petrossian K; Ye J; Warden C; Liu Z; Nishimura R; Osako T; Okido M; Shimada K; Takahashi M; Chu P; Yuan YC; Chen S Breast Cancer Res Treat; 2013 Jan; 137(1):93-107. PubMed ID: 23160924 [TBL] [Abstract][Full Text] [Related]
12. Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer. Wilson PM; Labonte MJ; Martin SC; Kuwahara ST; El-Khoueiry A; Lenz HJ; Ladner RD Invest New Drugs; 2013 Aug; 31(4):845-57. PubMed ID: 23299388 [TBL] [Abstract][Full Text] [Related]
13. The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer. Helland Ø; Popa M; Bischof K; Gjertsen BT; McCormack E; Bjørge L PLoS One; 2016; 11(6):e0158208. PubMed ID: 27352023 [TBL] [Abstract][Full Text] [Related]
14. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA). Mehdi O; Françoise S; Sofia CL; Urs G; Kevin Z; Bernard S; Igor S; Anabela CD; Dominique L; Eric M; Ali O Pancreatology; 2012; 12(2):146-55. PubMed ID: 22487525 [TBL] [Abstract][Full Text] [Related]
15. LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/STAT3/Akt pathway. Song X; Wang J; Zheng T; Song R; Liang Y; Bhatta N; Yin D; Pan S; Liu J; Jiang H; Liu L Mol Cancer; 2013 Oct; 12(1):114. PubMed ID: 24093956 [TBL] [Abstract][Full Text] [Related]
16. Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation. Kato Y; Egusa C; Maeda T; Tsuboi R J Dermatol Sci; 2016 Jan; 81(1):17-25. PubMed ID: 26596218 [TBL] [Abstract][Full Text] [Related]
17. In vivo monitoring of the anti-angiogenic therapeutic effect of the pan-deacetylase inhibitor panobinostat by small animal PET in a mouse model of gastrointestinal cancers. Maschauer S; Gahr S; Gandesiri M; Tripal P; Schneider-Stock R; Kuwert T; Ocker M; Prante O Nucl Med Biol; 2016 Jan; 43(1):27-34. PubMed ID: 26702784 [TBL] [Abstract][Full Text] [Related]
18. Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma. Jimura N; Fujii K; Qiao Z; Tsuchiya R; Yoshimatsu Y; Kondo T; Kanekura T J Dermatol Sci; 2021 Mar; 101(3):194-201. PubMed ID: 33531202 [TBL] [Abstract][Full Text] [Related]
19. Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells. Yan-Fang T; Zhi-Heng L; Li-Xiao X; Fang F; Jun L; Gang L; Lan C; Na-Na W; Xiao-Juan D; Li-Chao S; Wen-Li Z; Pei-Fang X; He Z; Guang-Hao S; Yan-Hong L; Yi-Ping L; Yun-Yun X; Hui-Ting Z; Yi W; Mei-Fang J; Lin L; Jian N; Shao-Yan H; Xue-Ming Z; Xing F; Jian W; Jian P PLoS One; 2015; 10(7):e0126566. PubMed ID: 26176219 [TBL] [Abstract][Full Text] [Related]
20. Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma. Kavanaugh SM; White LA; Kolesar JM Am J Health Syst Pharm; 2010 May; 67(10):793-7. PubMed ID: 20479100 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]